McCarthy JJ, McLeod HL & Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med 2013;5:189sr184.
Manolio TA. Incorporating whole-genome sequencing into primary care: falling barriers and next steps. Ann Intern Med 2017;167:204–205.
Armstrong K. Can genomics bend the cost curve? JAMA 2012;307:1031–1032.
Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang S-Y & Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med 2014;16:251–257.
Hatz MH, Schremser K & Rogowski WH. Is individualized medicine more cost-effective? A systematic review. PharmacoEconomics 2014;32:443–455.
Diamandis EP. The Hundred Person Wellness Project and Google’s Baseline Study: medical revolution or unnecessary and potentially harmful over-testing? BMC Med 2015;13:5.
Caulfield T, Evans J, McGuire A et al. Reflections on the cost of “low-cost” whole genome sequencing: framing the health policy debate. PLoS Biol 2013;11:e1001699.
Tsiplova K, Zur RM, Marshall CR et al. A microcosting and cost-consequence analysis of clinical genomic testing strategies in autism spectrum disorder. Genet Med 2017;19:1268–1275.
Sabatini LM, Mathews C, Ptak D et al. Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: a report of the Association for Molecular Pathology. J Mol Diagn 2016;18:319–328.
Sagoo GS, Norbury G, Mohammed S & Kroese M. Whole-Exome Sequencing in Clinical Genetics. A Health Economic Evaluation. PHG Foundation: Cambridge, UK, 2017.
Stark Z, Schofield D, Alam K et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med 2017;19:867–874.
Tan TY, Dillon OJ, Stark Z et al. Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions. JAMA Pediatr 2017;171:855–862.
Hegde M, Bale S, Bayrak-Toydemir P et al. Reporting incidental findings in genomic scale clinical sequencing—a clinical laboratory perspective: a report of the Association for Molecular Pathology. J Mol Diagn 2015;17:107–117.
Bennette CS, Gallego CJ, Burke W, Jarvik GP & Veenstra DL. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med 2015;17:587–595.
Christensen KD, Roberts JS, Whitehouse PJ et al. Disclosing pleiotropic effects during genetic risk assessment for Alzheimer disease. A randomized trial. Ann Intern Med 2016;164:155–163.
Phillips KA, Pletcher MJ & Ladabaum U. Is the “$1000 genome” really $1000? Understanding the full benefits and costs of genomic sequencing. Technol Health Care 2015;23:373–379.
Christensen KD, Vassy JL, Jamal L et al. Are physicians prepared for whole genome sequencing? A qualitative analysis. Clin Genet 2016;89:228–234.
Vassy JL, Christensen KD, Schonman EF et al. The impact of whole genome sequencing on the primary care and outcomes of healthy adult patients: a pilot randomized trial. Ann Intern Med 2017;167:159–169.
Vassy J, Lautenbach D, McLaughlin H et al. The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. Trials 2014;15:85.
McLaughlin HM, Ceyhan-Birsoy O, Christensen KD et al. A systematic approach to the reporting of medically relevant findings from whole genome sequencing. BMC Med Genet 2014;15:134.
Kong SW, Lee IH, Leshchiner I et al. Summarizing polygenic risks for complex diseases in a clinical whole-genome report. Genet Med 2015;17:536–544.
Vassy JL, McLaughlin HL, MacRae CA et al. A one-page summary report of genome sequencing for the healthy adult. Public Health Genomics 2015;18:123–129.
Cirino AL, Lakdawala NK, McDonough B et al. A comparison of whole genome sequencing to multigene panel testing in hypertrophic cardiomyopathy patients. Circ Cardiovasc Genet 2017;10:e001768.
Ramsey SD, Willke RJ, Glick H et al. Cost-effectiveness analysis alongside clinical trials II—an ISPOR Good Research Practices Task Force report. Value Health 2015;18:161–172.
Sanders GD, Neumann PJ, Basu A et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316:1093–1103.
Frick KD. Microcosting quantity data collection methods. Med Care 2009;47(7 suppl 1): S76–S81.
National Human Genome Research Institute. The cost of sequencing a human genome. 2016. https://www.genome.gov/sequencingcosts/. Accessed 30 Nov 2016.
Dukhovny D, Dennis CL, Hodnett E et al. Prospective economic evaluation of a peer support intervention for prevention of postpartum depression among high-risk women in Ontario, Canada. Am J Perinatol 2013;30:631–642.
Pagon RA, Tarczy-Hornoch P, Baskin PK et al. GeneTests-GeneClinics: genetic testing information for a growing audience. Hum Mutat 2002;19:501–509.
Hamosh A, Scott AF, Amberger J, Valle D & McKusick VA. Online Mendelian Inheritance in Man (OMIM). Hum Mutat 2000;15:57–61.
Kalia SS, Adelman K, Bale SJ et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017;19:249–255.
Dewey FE, Grove ME, Pan C et al. Clinical interpretation and implications of whole-genome sequencing. JAMA 2014;311:1035–1045.
Baudhuin LM, Lagerstedt SA, Klee EW, Fadra N, Oglesbee D & Ferber MJ. Confirming variants in next-generation sequencing panel testing by Sanger sequencing. J Mol Diagn 2015;17:456–461.
Walsh R, Thomson KL, Ware JS et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med 2017;19:192–203.
Chakravorty S & Hegde M. Gene and variant annotation for Mendelian disorders in the era of advanced sequencing technologies. Annu Rev Genomics Hum Genet 2017;18:229–256.
Berg JS, Foreman AK, O’Daniel JM et al. A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing. Genet Med 2016;18:467–475.
ClinGen Clinical Genome Resource. Actionability Working Group Evidence-based Summaries. 2017. https://www.clinicalgenome.org/working-groups/actionability/projects-initiatives/actionability-evidence-based-summaries/. Accessed 17 March 2017.
Yu J-H, Harrell TM, Jamal SM, Tabor HK & Bamshad MJ. Attitudes of genetics professionals toward the return of incidental results from exome and whole-genome sequencing. Am J Hum Genet 2014;95:77–84.
Kohane IS, Hsing M & Kong SW. Taxonomizing, sizing, and overcoming the incidentalome. Genet Med 2012;14:399–404.
Bustamante CD, Burchard EG & De La Vega FM. Genomics for the world. Nature 2011;475:163–165.